High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses.
about
N-terminal domain of Borna disease virus G (p56) protein is sufficient for virus receptor recognition and cell entryAttenuated vesicular stomatitis viruses as vaccine vectorsCharacterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins.Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vectorAnalysis of hemagglutinin-mediated entry tropism of H5N1 avian influenza.In Vitro and In Vivo Attenuation of Vesicular Stomatitis Virus (VSV) by Phosphoprotein Deletion.Inhibition of Lassa virus glycoprotein cleavage and multicycle replication by site 1 protease-adapted alpha(1)-antitrypsin variants.Characterization of Lassa virus glycoprotein oligomerization and influence of cholesterol on virus replication.Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunityRecombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity.Seroepidemiology of human metapneumovirus (hMPV) on the basis of a novel enzyme-linked immunosorbent assay utilizing hMPV fusion protein expressed in recombinant vesicular stomatitis virusVaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challengeCytoplasmic domain of Sendai virus HN protein contains a specific sequence required for its incorporation into virions.Pseudotypes of vesicular stomatitis virus with CD4 formed by clustering of membrane microdomains during buddingLive bivalent vaccine for parainfluenza and influenza virus infections.The membrane-proximal stem region of vesicular stomatitis virus G protein confers efficient virus assembly.Influenza virus assembly and lipid raft microdomains: a role for the cytoplasmic tails of the spike glycoproteins.Recombinant Newcastle disease virus as a vaccine vectorMeasles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence.A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.Virus-vectored influenza virus vaccines.A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animalsProperties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses.Heterologous exchanges of the glycoprotein and the matrix protein in a Novirhabdovirus.Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced diseaseNewcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza.Rhabdovirus-based vaccine platforms against henipavirusesNonsegmented negative-strand viruses as vaccine vectors.Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin.Anterograde or retrograde transsynaptic labeling of CNS neurons with vesicular stomatitis virus vectorsVesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus.Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infectionsA recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infectionImmunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1.Serological assays based on recombinant viral proteins for the diagnosis of arenavirus hemorrhagic fevers.Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein.Host cell factors and functions involved in vesicular stomatitis virus entry.Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity.Recombinant rinderpest vaccines expressing membrane-anchored proteins as genetic markers: evidence of exclusion of marker protein from the virus envelope.
P2860
Q24529164-7737A078-9B71-4278-8804-8A1ABDA4334DQ27469358-418AF92C-9783-4ABF-83F8-71A7C8964237Q27472885-4763FECF-8622-4825-9F20-D5806E524402Q27472940-7882D0C1-4C73-4B6A-B026-04C8E112B290Q30375938-5E923277-92AE-45C1-AA4F-CE63EA6FFD09Q30389455-F0958AA9-635B-4EFC-B48C-FA4D72D268B6Q33458341-909865D7-C2C2-442A-A611-00B783F439ABQ33558319-2D84FD45-D1F0-4DEA-9723-084FD15B0EB7Q33648987-08166E98-D0B0-4972-91C0-1DAEF1F471A9Q33713903-B6F8C491-8D7E-4BF8-972F-B80B71DE88FBQ33752841-B7624B79-88A7-4BD5-AF4C-9C0968E6C74FQ33783986-26C208B7-60C4-43CB-84C3-A01B4079319EQ33786023-30F1C9FA-63B0-4069-9A09-F7ECA78EBBC1Q33788688-063E9B2E-1E55-4AF2-A796-88F81AA8DBE6Q33788756-1BD2AC2F-259A-47AA-9957-69097A335472Q33798704-EAB2D708-909B-4850-A2E1-5B40F5FDC6D3Q33804501-CDD9DA51-256A-4B90-AF9F-289DA371C828Q33850246-F5D66549-A37B-45D7-A0DE-E8BCBD55F957Q34069549-FEEF73AC-E656-440E-A5CC-7677A9151050Q34092753-8D993D0C-80C2-426A-A14B-23B0AA94CE79Q34102268-3C16B8A0-B532-4C5C-9233-0DDCFF2F3A25Q34228558-7BCD37A5-36D0-4638-AF9C-8BE8D161F037Q34317031-4BD3ACB1-DFDA-4F9F-97F6-408CDF0AE36CQ34332631-1FC7CF16-D8CC-40A7-86F5-FC31ACD45A9FQ34344372-8961E366-AD74-46EA-B524-4A238592C5C2Q34650303-029D583F-B038-474E-A3F4-9E208C6837FFQ34992537-E4E3F629-E405-447C-B596-490FA7705146Q35139219-37F9B786-2F37-46B0-9745-F6D9690F0B54Q35155045-6B267D20-E750-4E9B-B00E-8B55A90A577EQ35217191-91440EAD-8464-4788-9AAA-4E20DEC16BA8Q35531542-652AC878-07D2-4D46-B9D3-E30B148F63FDQ35557184-C704990D-54AF-493E-B37C-83871555C664Q35853085-F2B9717E-034F-43EF-838F-6B8BC4E77D68Q36190495-8F4EC636-4BE8-445E-BA89-A4762B510104Q36395853-AAC1BF8A-3153-4041-8BF8-27D92B1111AEQ36509916-8C0C0960-8766-4B7F-8513-4ADF5558C30BQ37033185-DA3FA21F-AB5C-43F5-87B0-21536DACDB29Q37066697-1B9680AF-32E3-4869-A017-A8CB5CDD26E4Q37243886-A3F1BDF6-C899-4958-ABAA-D6EE826983D5Q39539598-CC3089F3-1FE9-4425-A2BA-8B97AB8F853D
P2860
High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
High-efficiency incorporation ...... vesicular stomatitis viruses.
@ast
High-efficiency incorporation ...... vesicular stomatitis viruses.
@en
type
label
High-efficiency incorporation ...... vesicular stomatitis viruses.
@ast
High-efficiency incorporation ...... vesicular stomatitis viruses.
@en
prefLabel
High-efficiency incorporation ...... vesicular stomatitis viruses.
@ast
High-efficiency incorporation ...... vesicular stomatitis viruses.
@en
P2093
P2860
P1433
P1476
High-efficiency incorporation ...... t vesicular stomatitis viruses
@en
P2093
E Kretzschmar
L Buonocore
M J Schnell
P2860
P304
P407
P577
1997-08-01T00:00:00Z